Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Dual mode accommodating-disaccommodating IOL with zonular capture haptics

Search Title by author or title

Session Details

Session Title: Pseudophakic IOLs: Toric, Multifocal, Accommodative

Session Date/Time: Monday 09/10/2017 | 14:30-16:00

Paper Time: 15:40

Venue: Room 4.1

First Author: : P.Beer USA

Co Author(s): :                        

Abstract Details


To evaluate the performance of a novel accommodative-disaccomodative IOL with zonular capture haptics. This dual mode AD-IOL has a flexible, fluid filled optic that exhibits both axial shift and shape shift. The optic is driven by a proven haptic structure. The maximum possible amplitude of accommodation is 30 diopters on over the full range of motion of the haptics. The haptic structure realizes one half to one third of that movement amplitude in the eye with an expected range of accommodation in vivo of 15-10 diopters.


Cleveland Clinic Foundation, Learner Research Institute


Our zonular capture haptic system has been proven to capture the movement of the young crystalline lens in a primate model in our previous iteration of an axial shift IOL. These results were previously presented. In order to maximize our accommodative gain, we have adapted a flexible optic that exhibits shape shift in addition to the axial shift. This optic is driven by the haptic structure, it is similar in size to a monofocal IOL optic and does not require any internal components. It functions in closed bag environment, similar to standard IOL’s.


Over the full range of haptic flexion, this IOL exhibits 125 D of accommodation in air, or 31.25D of accommodation in water. The radius of curvature of the accommodative surface changes from 15.75mm in disaccommodated state to 3.19mm in accommodated state. Additional testing is ongoing and forthcoming results will be presented.


This Dual Mode AD-IOL with Zonular Capture Haptics is expected to provide a viable cure for presbyopia at the time of cataract surgery.

Financial Disclosure:

gains financially from product or procedure presented, has significant investment interest in a company producing, developing or supplying product or procedure presented

Back to previous